Charles Schwab Investment Management Inc. Buys 40,644 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Charles Schwab Investment Management Inc. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 554,606 shares of the biopharmaceutical company's stock after buying an additional 40,644 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.43% of Alnylam Pharmaceuticals worth $149,755,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $28,000. Whipplewood Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. boosted its stake in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $35,000. Finally, Washington Trust Advisors Inc. boosted its stake in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $10.28 during midday trading on Thursday, reaching $442.80. The company's stock had a trading volume of 1,136,458 shares, compared to its average volume of 951,044. The stock has a market cap of $58.04 billion, a P/E ratio of -179.27 and a beta of 0.25. The company has a fifty day simple moving average of $339.44 and a 200 day simple moving average of $287.99. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $445.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the firm posted ($0.13) EPS. The company's revenue was up 17.3% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research note on Friday, August 1st. UBS Group raised their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. BMO Capital Markets upped their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday, June 24th. Finally, Oppenheimer raised Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price for the company in a report on Monday, August 4th. Four analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $403.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.